Compare TDOC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | KALV |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2015 | 2014 |
| Metric | TDOC | KALV |
|---|---|---|
| Price | $6.77 | $26.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | $7.56 | ★ $32.60 |
| AVG Volume (30 Days) | ★ 5.1M | 4.3M |
| Earning Date | 04-29-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,406,840,000.00 | $50,000,000.00 |
| Revenue This Year | $1.19 | $185.42 |
| Revenue Next Year | $1.25 | $59.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.41 | ★ 495.66 |
| 52 Week Low | $4.40 | $9.83 |
| 52 Week High | $9.77 | $26.85 |
| Indicator | TDOC | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 64.27 | 75.30 |
| Support Level | $6.74 | $14.66 |
| Resistance Level | $7.95 | N/A |
| Average True Range (ATR) | 0.38 | 0.39 |
| MACD | 0.07 | 0.25 |
| Stochastic Oscillator | 72.45 | 98.72 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.